{"id":"W4395663602","doi":"10.1158/2767-9764.crc-23-0459","title":"First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study","year":2024,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston Health Sciences Centre","funders":"Merck KGaA; Pfizer","keywords":"Javelin; Avelumab; Chemotherapy; Medicine; Solid tumor; Oncology; Internal medicine; Cancer; Immunotherapy; Pembrolizumab; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001197105,0.0004568179,0.0008671373,0.0001879635,0.0001718781,0.0006689525,0.0003984086,0.0005315499,0.001690224],"category_scores_gemma":[0.0007281704,0.0002038524,0.0009397505,0.0002574555,0.0003083439,0.0004962133,0.0002565738,0.001475255,0.0004131436],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006113549,"about_ca_system_score_gemma":0.0009052792,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006785005,"about_ca_topic_score_gemma":0.002669194,"domain_scores_codex":[0.9996474,0.0001968967,0.00002154103,0.00004914459,0.0000450358,0.00003996211],"domain_scores_gemma":[0.9994116,0.00008632892,0.0001625275,0.00004835567,0.00004895082,0.0002422647],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5088803,0.04198851,0.03979178,0.002793415,0.003873277,0.0002794627,0.0003252616,0.003513258,0.05689209,0.0004692182,0.01560241,0.325591],"study_design_scores_gemma":[0.4672447,0.3971245,0.09410829,0.0003061444,0.00280489,0.0009789468,0.0001408563,0.002922183,0.01160752,0.0003511256,0.02234641,0.00006445153],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837683,0.01054134,0.0004197829,0.0006402089,0.00008992316,0.0005804627,0.001525864,0.00006215007,0.002371849],"genre_scores_gemma":[0.9832141,0.005948255,0.001512743,0.001290512,0.0001579305,0.0004950301,0.004682164,0.00003239817,0.002666801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001690224,"threshold_uncertainty_score":0.006330967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08169363019912536,"score_gpt":0.4397402393431038,"score_spread":0.3580466091439785,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}